MCID: ADN009
MIFTS: 48

Adenosquamous Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 15 17 71
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 44
Carcinoma Adenosquamous 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 44 D018196
NCIt 50 C3727
SNOMED-CT 67 403902008
UMLS 71 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to esophageal adenosquamous carcinoma and adenosquamous lung carcinoma. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Doxorubicin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include cervix, pancreas and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 639)
# Related Disease Score Top Affiliating Genes
1 esophageal adenosquamous carcinoma 32.5 TP53 KRT7 KRT5 CEACAM5
2 adenosquamous lung carcinoma 32.3 PIK3CA KRAS EGFR
3 cervical adenocarcinoma 31.0 TP53 KRT7 KRAS EGFR CEACAM7 CEACAM5
4 pancreatic ductal adenocarcinoma 30.9 TP53 SMAD4 MUC1 KRAS EGFR
5 subareolar duct papillomatosis 30.7 KRT8 KRT7 KRT5
6 gallbladder adenocarcinoma 30.7 TP53 PIK3CA EGFR
7 gallbladder cancer 30.7 TP53 PIK3CA MUC1 KRAS EGFR CEACAM5
8 tubular adenocarcinoma 30.7 SYP MUC1 KRT7 EGFR CEACAM5
9 cervix carcinoma 30.6 TP53 PIK3CA KRT7 EGFR CEACAM5
10 pancreatic adenocarcinoma 30.6 TP53 SMAD4 PIK3CA MUC4 KRAS EGFR
11 oral cancer 30.6 TP53 KRT19 EGFR
12 signet ring cell adenocarcinoma 30.6 TP53 MUC1 KRT7 KRAS CEACAM5
13 barrett esophagus 30.6 TP53 SMAD4 KRT7 AR
14 intrahepatic cholangiocarcinoma 30.6 TP53 SMAD4 MUC4 MUC1 KRT7 KRT19
15 leukoplakia of penis 30.5 KRT7 CEACAM5
16 gastric adenocarcinoma 30.5 TP53 SMAD4 PIK3CA KRAS CEACAM5
17 cervical cancer 30.5 TP63 TP53 SMAD4 PIK3CA KRT19
18 bile duct cysts 30.5 KRT7 KRT19 KRAS CEACAM5
19 lung squamous cell carcinoma 30.5 TP63 TP53 PIK3CA KRT19 KRAS EGFR
20 papilloma 30.5 TP63 TP53 KRT8 KRT7 KRT5 KRAS
21 klatskin's tumor 30.5 TP53 KRT7 KRT19 CEACAM5
22 squamous cell carcinoma 30.5 TP63 TP53 SMAD4 PIK3CA MUC1 KRT7
23 gallbladder squamous cell carcinoma 30.5 KRT5 CEACAM5
24 appendix adenocarcinoma 30.4 SYP KRT7 KRAS CEACAM5
25 skin benign neoplasm 30.4 TP63 SERPINA3 KRT7 KRT5
26 bile duct cystadenocarcinoma 30.4 MUC1 KRT7 CEACAM5
27 adenocarcinoma in situ 30.4 KRT7 KRAS CEACAM5
28 cystadenoma 30.4 SYP SERPINA3 MUC1 KRT7 CEACAM5
29 endometrial adenocarcinoma 30.4 TP53 MUC1 KRT7 KRAS EGFR
30 mucoepidermoid esophageal carcinoma 30.4 TP53 KRT5 CEACAM5
31 in situ carcinoma 30.4 TP53 SERPINA3 PIK3CA MUC1 KRT8 KRT5
32 gastric squamous cell carcinoma 30.3 SERPINA3 KRT7 KRT5
33 carcinosarcoma 30.3 TP53 PIK3CA MUC1 KRT7 KRAS EGFR
34 cystic teratoma 30.3 TP53 SYP NKX2-1 KRT7 KRAS
35 spindle cell sarcoma 30.3 SERPINA3 MUC1 KRT7
36 necrotizing sialometaplasia 30.3 TP63 TP53 KRT7 KRT5
37 mature teratoma 30.3 TP53 SYP KRT7 KRAS CEACAM5
38 cervical squamous cell carcinoma 30.3 TP63 TP53 PIK3CA KRT8 KRAS EGFR
39 endocervical adenocarcinoma 30.3 TP53 PIK3CA MUC1 KRT7 CEACAM5
40 breast metaplastic carcinoma 30.2 MAML2 KRT7 KRT5 EGFR
41 adenoid squamous cell carcinoma 30.2 KRT8 KRT7 KRT5 KRT19
42 lynch syndrome 30.2 TP53 SMAD4 PIK3CA KRAS EGFR
43 syringocystadenoma papilliferum 30.2 SERPINA3 MUC1 KRT19 KRAS
44 acinar cell carcinoma 30.2 TP53 SMAD4 SERPINA3 KRT7
45 teratoma 30.2 TP53 SYP NKX2-1 KRT7 KRAS CEACAM5
46 secretory meningioma 30.1 SERPINA3 MUC1 KRT7 CEACAM7 CEACAM5
47 lymphoepithelioma-like carcinoma 30.1 MUC1 KRT8 KRT7 KRT5 KRT19
48 cystadenocarcinoma 30.1 TP53 SERPINA3 PIK3CA MUC1 KRT7 CEACAM5
49 papillary squamous carcinoma 30.1 SYP KRT7 KRT5 EGFR CEACAM5
50 large cell neuroendocrine carcinoma 30.0 SYP NKX2-1 KRT7 EGFR

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.64 EGFR KRAS MUC1 PIK3CA
2 Decreased viability GR00055-A-2 9.64 EGFR KRAS MUC1 PIK3CA
3 Decreased viability GR00055-A-3 9.64 KRAS
4 Decreased viability GR00106-A-0 9.64 KRAS
5 Decreased viability GR00221-A-1 9.64 EGFR KRAS PIK3CA
6 Decreased viability GR00221-A-2 9.64 KRAS PIK3CA
7 Decreased viability GR00221-A-4 9.64 EGFR PIK3CA
8 Decreased viability GR00249-S 9.64 MUC1
9 Decreased viability GR00301-A 9.64 KRAS
10 Decreased viability GR00381-A-1 9.64 KRAS
11 Decreased viability GR00402-S-2 9.64 PIK3CA
12 Decreased cell migration GR00055-A-1 9.13 CTSD
13 Decreased cell migration GR00055-A-3 9.13 EGFR PIK3CA

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.2 AR CTSD EGFR KRAS KRT19 KRT5
2 integument MP:0010771 10.11 AR CTSD EGFR KRAS KRT19 KRT5
3 endocrine/exocrine gland MP:0005379 10.1 AR CTSD EGFR KRAS KRT19 NKX2-1
4 embryo MP:0005380 10.09 AR EGFR KRAS KRT19 KRT8 PIK3CA
5 craniofacial MP:0005382 10.08 AR EGFR KRAS KRT19 KRT5 SMAD4
6 neoplasm MP:0002006 9.91 AR EGFR KRAS KRT19 NKX2-1 PIK3CA
7 limbs/digits/tail MP:0005371 9.87 AR EGFR KRAS KRT5 SMAD4 TP53
8 no phenotypic analysis MP:0003012 9.7 EGFR KRAS KRT19 NKX2-1 PIK3CA TP53
9 normal MP:0002873 9.61 AR EGFR KRAS KRT19 NKX2-1 SMAD4
10 reproductive system MP:0005389 9.32 AR EGFR KRAS KRT19 KRT8 NKX2-1

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
4
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Fluorouracil Approved Phase 3 51-21-8 3385
7
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
8
leucovorin Approved Phase 3 58-05-9 6006
9
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
10
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
11
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
12
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
13
Tirapazamine Investigational Phase 3 27314-97-2
14
Liposomal doxorubicin Phase 3 31703
15 Adjuvants, Immunologic Phase 3
16 Hematinics Phase 3
17 Epoetin alfa Phase 3 113427-24-0
18 Antiviral Agents Phase 3
19 Antimetabolites Phase 3
20 Nutrients Phase 3
21 Protective Agents Phase 3
22 Micronutrients Phase 3
23 Trace Elements Phase 3
24 Vitamins Phase 3
25 Hormones Phase 3
26 topoisomerase I inhibitors Phase 3
27 Calcium, Dietary Phase 3
28 Antidotes Phase 3
29 Albumin-Bound Paclitaxel Phase 3
30 Tubulin Modulators Phase 3
31 Antimitotic Agents Phase 3
32 Mitogens Phase 3
33 Immunoglobulins Phase 3
34 Antibodies Phase 3
35 Antibodies, Monoclonal Phase 3
36 Protein Kinase Inhibitors Phase 3
37 Insulin, Globin Zinc Phase 3
38 insulin Phase 3
39
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
40
Calcium Nutraceutical Phase 3 7440-70-2 271
41
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
42
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
43
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
44
Metformin Approved Phase 2 657-24-9 14219 4091
45
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
46
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3
48
Etoposide Approved Phase 2 33419-42-0 36462
49
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
50
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
2 A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy Completed NCT01365156 Phase 3
3 Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer Completed NCT00017004 Phase 3 Cisplatin
4 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
5 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
6 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
7 A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer Recruiting NCT04340141 Phase 3 Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil
8 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) Recruiting NCT01101451 Phase 3 Cisplatin
9 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
10 Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
11 Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
12 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
13 Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib;Erlotinib
14 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
15 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
16 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin
17 A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
18 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
19 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT01266460 Phase 2
20 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
21 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
22 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
23 A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers Completed NCT00126581 Phase 2 Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
24 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
25 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
26 A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048) Completed NCT01267253 Phase 2 Brivanib Alaninate
27 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
28 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
29 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
30 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
31 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
32 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
33 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
34 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
35 A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer Completed NCT02921269 Phase 2 Atezolizumab
36 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
37 Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
38 Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma Recruiting NCT03469531 Phase 2 Nimotuzumab;Cisplatin
39 The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial Recruiting NCT02394652 Phase 2 Metformin;Cisplatin;FAZA
40 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
41 A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
42 A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer Active, not recruiting NCT02257528 Phase 2
43 A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
44 Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma: A Multicenter, Open-label, Randomized, Control Phase II Study(ARISE) Not yet recruiting NCT04354961 Phase 2 Almonertinib;Paclitaxel and carboplatin
45 A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) Not yet recruiting NCT03834571 Phase 2 Carboplatin;Cisplatin;Paclitaxel
46 A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes (TIL) Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen Suspended NCT02133196 Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
47 A Phase I/II Trial of Abraxane in Combination With Carboplatin, Erbitux and Intensity Modulated Radiation Therapy (IMRT)for Treatment of Locally Advanced Squamous Cancer of the Head and Neck Terminated NCT00570674 Phase 1, Phase 2 Abraxane;Erbitux;Carboplatin
48 A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas Terminated NCT02868892 Phase 2 Pemetrexed
49 A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer Terminated NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
50 A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma Withdrawn NCT01301612 Phase 2 Nimotuzumab;Cisplatin;Cisplatin

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

40
Cervix, Pancreas, Colon, Lymph Node, Prostate, Thyroid, Ovary

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 1838)
# Title Authors PMID Year
1
Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. 54 61
19859629 2009
2
Large cell carcinoma of the lung: an endangered species? 54 61
19444077 2009
3
Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. 54 61
19514842 2009
4
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. 54 61
19563658 2009
5
Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining. 61 54
19278431 2009
6
Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. 54 61
18992960 2009
7
Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). 54 61
18836809 2008
8
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. 61 54
17581404 2007
9
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. 61 54
17186532 2007
10
Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. 61 54
17090193 2006
11
The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer. 61 54
17036524 2006
12
Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. 54 61
16187277 2006
13
Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon. 54 61
15864702 2005
14
Unique characteristics of rectal carcinoma cell lines derived from invasive carcinomas in ulcerative colitis patients. 61 54
15016319 2004
15
Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. 54 61
14610320 2003
16
Colliding primary lung cancers of adenosquamous carcinoma and large cell neuroendocrine carcinoma. 54 61
12558872 2003
17
Neuroendocrine marker expression in cervical carcinomas of non-small cell type. 61 54
12352185 2002
18
Primary adenosquamous carcinoma of the liver which produces granulocyte-colony-stimulating factor and parathyroid hormone related protein: association with leukocytosis and hypercalcemia. 61 54
11506305 2001
19
Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. 61 54
11381365 2001
20
Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. 54 61
11006578 2000
21
EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. 61 54
9588219 1998
22
Different angiogenic pathways in human cervical cancers. 61 54
9454658 1998
23
Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. 54 61
7671236 1995
24
Epidermal growth factor receptor (EGF-R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers. 61 54
7654016 1995
25
Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. 61 54
7736397 1995
26
Hypercalcaemia in a patient with fatal adenosquamous carcinoma of the colon. 61 54
8107631 1994
27
Cathepsin-D expression in cervical carcinoma and its prognostic significance. 54 61
8322451 1993
28
Immunocytologic diagnosis of small-cell lung cancer in imprint smears. 61 54
1656682 1991
29
[A parathyroid hormone related protein (PTHrP) implicated in hypercalcemia associated with malignancy: research of the PTHrP for novel hormonal tumor marker]. 54 61
2348564 1990
30
Clinical and Histological Basis of Adenosquamous Carcinoma of the Pancreas: A 30-year Experience. 61
33190924 2021
31
Adenosquamous carcinoma of the breast, an uncommon diagnosis with poor prognosis-Lessons learned from a 12-year analysis of the National Cancer Database. 61
33482684 2021
32
Pancreatic panniculitis in a patient with pancreatic adenosquamous carcinoma. 61
33124679 2021
33
An Australian, single-centre study of surgical management outcomes for early-stage cervical cancer. 61
33176013 2021
34
Updates on World Health Organization classification and staging of esophageal tumors: implications for future clinical practice. 61
33157124 2021
35
Adenosquamous carcinoma of the breast: a population-based study. 61
33580464 2021
36
Syringomatous adenoma of the nipple with microcalcifications on mammography: A case report. 61
33368840 2021
37
Gastric-type cervical adenocarcinoma with squamous differentiation: buried in adenosquamous carcinomas? 61
33404855 2021
38
Impact of histological subtype on the response to chemoradiation in locally advanced cervical cancer and the possible role of surgery. 61
33363604 2021
39
Analysis of risk factors for patients with early-stage cervical cancer: A study of 374 patients. 61
33078517 2021
40
The origins and consequences of UPF1 variants in pancreatic adenosquamous carcinoma. 61
33404013 2021
41
Analysis of clinical characteristics and prognosis with cervical adenosquamous carcinoma: a large population-based study. 61
33478265 2021
42
Spatially Fractionated Radiation Therapy Using Lattice Radiation in Far-advanced Bulky Cervical Cancer: A Clinical and Molecular Imaging and Outcome Study. 61
32853384 2020
43
Minimally invasive versus open radical trachelectomy for early-stage cervical cancer: protocol for a multicenter randomized controlled trial in China. 61
33317612 2020
44
Survival after minimally invasive surgery in early cervical cancer: is the intra-uterine manipulator to blame? 61
33037109 2020
45
[A Case of Metastatic Small Intestinal Tumor Diagnosed with Intestinal Obstruction]. 61
33468965 2020
46
Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. 61
33137577 2020
47
Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. 61
32639612 2020
48
Efficacy and Safety of 8 spheres Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Locally Advanced Non-small Cell Lung Cancer. 61
33332223 2020
49
Standard ultrastaging compared to one-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer. 61
33127865 2020
50
Conjunctival Adenosquamous Carcinoma Lacks MAML2 Translocation: A Variant of Squamous Cell Carcinoma With Mucoepidermoid Differentiation and Aggressive Behavior? 61
32476556 2020

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 SMAD4 PIK3CA KRT8 KRT7 KRT5 KRT19
2
Show member pathways
12.72 TP53 SMAD4 PIK3CA KRAS EGFR AR
3
Show member pathways
12.69 TP53 SMAD4 PIK3CA KRAS EGFR
4 12.66 TP53 SMAD4 PIK3CA KRAS EGFR AR
5
Show member pathways
12.62 TP63 TP53 PIK3CA KRAS CTSD
6
Show member pathways
12.58 PIK3CA KRT19 KRAS EGFR CTSD
7 12.43 TP63 TP53 PIK3CA KRAS EGFR
8 12.41 MUC1 KRT8 KRT7 KRT5 KRT19
9 12.26 TP53 SMAD4 PIK3CA KRAS
10
Show member pathways
12.25 PIK3CA MUC1 KRAS EGFR
11
Show member pathways
12.24 TP53 PIK3CA EGFR AR
12 12.22 TP53 PIK3CA KRAS EGFR
13
Show member pathways
12.14 TP53 PIK3CA KRAS EGFR AR
14 12.1 TP53 SMAD4 KRAS EGFR
15
Show member pathways
11.99 SMAD4 PIK3CA KRAS EGFR
16 11.93 TP63 TP53 EGFR CTSD
17 11.81 TP53 PIK3CA KRAS CTSD
18 11.73 TP53 SMAD4 PIK3CA KRAS
19 11.67 TP53 KRAS EGFR
20
Show member pathways
11.66 KRT8 KRT7 KRT5 KRT19
21
Show member pathways
11.57 TP53 SMAD4 PIK3CA MUC1 KRAS EGFR
22 11.54 TP53 SMAD4 KRAS EGFR AR
23 11.37 TP53 SMAD4 CTSD
24 11.3 TP53 PIK3CA KRAS EGFR
25 11.2 TP53 KRT8 KRT19
26 11.06 SMAD4 KRAS EGFR
27 10.86 PIK3CA KRAS EGFR

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.28 SERPINA3 MUC4 MUC1 KRT8 KRT7 KRT5
2 intermediate filament GO:0005882 9.26 KRT8 KRT7 KRT5 KRT19

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.87 TP63 TP53 SMAD4 NKX2-1 MAML2 EGFR
2 keratinization GO:0031424 9.67 KRT8 KRT7 KRT5 KRT19
3 positive regulation of transcription, DNA-templated GO:0045893 9.63 TP63 TP53 SMAD4 NKX2-1 EGFR AR
4 Leydig cell differentiation GO:0033327 9.4 NKX2-1 AR
5 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.26 TP53 MUC1
6 cell differentiation involved in embryonic placenta development GO:0060706 8.96 KRT8 KRT19
7 cornification GO:0070268 8.92 KRT8 KRT7 KRT5 KRT19

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.65 TP63 TP53 SMAD4 EGFR AR
2 p53 binding GO:0002039 9.33 TP63 TP53 MUC1
3 MDM2/MDM4 family protein binding GO:0097371 9.32 TP63 TP53
4 RNA polymerase II transcription factor binding GO:0001085 9.13 TP53 SMAD4 AR
5 transcription regulatory region sequence-specific DNA binding GO:0000976 9.02 TP63 TP53 SMAD4 NKX2-1 AR

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....